Uncertainty on the effectiveness and safety of rivaroxaban in premenopausal women with atrial fibrillation: empirical evidence needed

Table 2 The value of reducing the decision uncertainty surrounding the choice between either rivaroxaban (RVX) or vitamin K antagonists (VKAs) in premenopausal women with atrial fibrillation in the Netherlands

^aRepresents the chance that the female patient with atrial fibrillation belongs to the respective age category
^bExpected value of perfect information, which equals the outcomes (in terms of QALYs or NMB) when making treatment decisions under perfect information, subtracted with the outcomes when making decisions under current uncertainty. The EVPI consequently also equals the maximum value of information that can be gained with further research
^cWe assumed that the probability of having suffered a previous stroke increases with age: 0.5% in women aged 20; 1% in women aged 30; 2% in women aged 40; and 5% in women aged 50 years

ISSN: 1471-2261